AI assistant
DBV Technologies S.A. — Regulatory Filings 2015
Jan 14, 2015
33512_ffr_2015-01-14_a9fa49b9-19be-4561-85d9-80269b2cb112.zip
Regulatory Filings
Open in viewerOpens in your device viewer
6-K 1 d851821d6k.htm 6-K 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2015
Commission File Number: 001-36697
DBV TECHNOLOGIES S.A.
(Translation of registrants name into English)
Green Square-Bâtiment D
80/84 rue des Meuniers
92220 Bagneux France
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXHIBITS
| Exhibit | Description |
|---|---|
| 99.1 | Half Year Update on the DBV Technologies Liquidity Agreement dated January 14, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| /s/ David Schilansky |
|---|
| David Schilansky |
| Chief Financial Officer |
Exhibit 99.1
Half year update on the DBV Technologies liquidity agreement
Bagneux, France, January 14, 2015 Under the liquidity agreement signed between DBV TECHNOLOGIES and NATIXIS, the following resources were listed in the liquidity account on December 31st, 2014:
8 054 DBV TECHNOLOGIES shares
1,111,227.16
As a reminder, during the last half year liquidity agreement on June 30th, 2014, the following assets appeared on the liquidity account:
9,018 DBV TECHNOLOGIES shares
478,300.41
Under the terms of the liquidity contract, pursuant to Article 12, it is recalled that the following resources have been added as of December 15, 2014:
- EUR 600,000.00
It is specified that at the implementation of the said contract the following resources were listed in the liquidity account:
| - | 0 titres DBV TECHNOLOGIES shares |
|---|---|
| - | EUR 300,000.00 |
About DBV Technologies
DBV Technologies is developing Viaskin ® , an innovative new approach to the treatment of allergies a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin ® Peanut and Viaskin ® Milk. The clinical development program for Viaskin ® Peanut has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT).
DBV Technologies Contacts
| David Schilansky Chief Operating
Officer Tel. : +33(0)1 55 42 78 75 [email protected] | |
| --- | --- |
| Susanna Mesa VP Finance, US Investor
Relations & Strategy Tel. : +1 917-346-3447 [email protected] | Nathalie Donne Director, Corporate
Communication & Business Development Tel. : +33(0)1 55 42 78 72 [email protected] |
| DBV IR and Media Contacts | |
| Todd James U.S. Investor Relations The Trout Group Tel. : +1 646-378-2926 [email protected] | Marion Janic US Media Relations Rooney & Associates Tel. : +1-212-223-4017 [email protected] |